Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)

Historic Preferred Stock Liabilities for C4 Therapeutics (CCCC) over the last 2 years, with Q3 2020 value amounting to $256.5 million.

  • C4 Therapeutics' Preferred Stock Liabilities rose 13321.06% to $256.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $256.5 million, marking a year-over-year increase of 13321.06%. This contributed to the annual value of $111.0 million for FY2019, which is N/A changed from last year.
  • C4 Therapeutics' Preferred Stock Liabilities amounted to $256.5 million in Q3 2020, which was up 13321.06% from $111.0 million recorded in Q4 2019.
  • C4 Therapeutics' Preferred Stock Liabilities' 5-year high stood at $256.5 million during Q3 2020, with a 5-year trough of $110.0 million in Q3 2019.